
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Atlantic Research Group, Inc. (ARG)-a rare disease-focused contract research organization (CRO)-announced that it formed its rare disease strategic advisory board (SAB). The SAB will consist of outside scientific experts, patient advocates, and former executives from rare disease-focused biotechs.
Read the full release






